Conference Coverage
The Latest
Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions
Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.
Indigenous People and Global Migrants Face Similar Issues Accessing Health Care
Hostilities against migrants and indigenous people are also threats to their health.
Some Research on Pregnant and Postpartum Women with HIV Is Presented at CROI, But More Trials Are Needed
Pregnant people who are living with or vulnerable to HIV need to be included in clinical trials in order to close our knowledge gaps.
Durable HIV Remission in London Patient, the Second Person Cured of HIV
Researchers are happy but cautious, because this isn’t a strategy for most people with HIV.
IDWeek 2019: What to Expect at This Year's Conference
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
Global Health Researchers and Activists Grapple With Complex Needs of Migrants Living With HIV
Recent Trump administration policies on migrants living with HIV have prompted a response from the international AIDS research community.
Meet Young People on Their Own Terms and Don’t Judge Their Sex Lives, Experts Agree
Nonjudgmental services and innovative ways to talk to youth about sex should be at the core of any sexual health plan.
Indigenous Communities in Mexico and Elsewhere Demand a Seat at the Table
"We have never been silent, but you have not heard us": Advocates demonstrate to demand inclusion of indigenous issues in the HIV response.
Marginalized Groups Are Focus of IAS 2019 Forum
Activists working on human rights discuss the challenges of achieving an end to the HIV epidemic.
Experts Flummoxed By Conflicting New Data on STIs, HIV, and Long-Term Contraception in Sub-Saharan Africa
ECHO trial results and follow-up studies find unexpectedly low rates of some STIs among users of certain long-term hormonal contraceptives. They also find high HIV rates (unrelated to the contraceptives) that suggest considerable value for PrEP integration.